overview of the 2011 work programme paul griffiths scientific committee meeting, lisbon, november...
TRANSCRIPT
Overview of the 2011 Work Programme
Paul Griffiths
Scientific committee meeting, Lisbon, November 2010
2
Overview
• Three-year strategy (2010–2012) will be implemented through 3 annual work plans, 2011 WP is the 2’nd
• Heart of the agency work remains:• State of the art review of the drug phenomenon• Maintaining an up to date reference point on drugs• Providing ongoing support to EU institution and
Member states for monitoring and implementing the EU strategy and action plan
2011 WP
Highlights
Core activities
Key indicators
Monitoring responses
Transversal analysis
Supplyreduction
3
2011 focus
• Ensuring European system fits for the purpose & remaining responsive to developments
• Further dissemination of best practice• Developing information sources in supply
reduction• Support the evaluation of the EU strategy and
action plan• Focus on polydrug use, combined analysis,
policy-relevance analysis• Dissemination and valorising EMCDDA
findings
2011 WP
Highlights
Core activities
Key indicators
Monitoring responses
Transversal analysis
Supplyreduction
4
State of the art review
• Preparation of the Annual report package• Efficient and methodologically sound data
input, management and processing• Top level strategic review of data
collected and appropriateness of the instruments used
• Continue development of statistical bulletin
• Further technical development of FONTE and data warehouse
2011 WP
Highlights
Core activities
Key indicators
Monitoring responses
Transversal analysis
Supplyreduction
5
Remain methodologically sound
• Efficient collection and analysis of the KIs• Maintaining and strengthen network• Increase quality and comparability
• Better integration of youth survey (GPS)• Final stage of rationalisation of TDI• Broadening scope of PDU• Update protocol of DRID• Improve tools for mortality cohort data collection• New data lab workshop (GPS, mortality registries)
2011 WP
Highlights
Core activities
Key indicators
Monitoring responses
Transversal analysis
Supplyreduction
6
Support to EC and rationalise data collection
• Support to the Council recommendation on prevention and reduction of health related harm
• Investigate and develop models for collecting data on:• Opiates substitution treatment• GPs• Low-threshold agencies
• Cochrane systematic review on media campaigns
• Conceptual framework for coherent set of response indicators
2011 WP
Highlights
Core activities
Key indicators
Monitoring responses
Transversal analysis
Supplyreduction
7
Cross analysis and CUPs
2011 WP
Highlights
Core activities
Key indicators
Monitoring responses
Transversal analysis
Supplyreduction
• Treatment coverage in subgroups of users• Alcohol cannabis connections• Polydrug use• Drugs and driving
• CUP treatment: coherent supportive and scientifically sound approach for monitoring treatment in Europe
• CUP prison: scale up monitoring of prison setting• CUP modelling: identify and support policy relevant
analyses
8
Development and adoption of indicators 2011 WP
Highlights
Core activities
Key indicators
Monitoring responses
Transversal analysis
Supplyreduction
• Improving understanding of Europe’s specialised police units
• 3 expert groups (drug markets, drug-related crime, drug supply reduction)
• Second technical conference on DSSR
9
Combine EWS and emerging trends
2011 WP
New drugs
Policy
Goodpractice
Main outputs
• Implement efficiently Council Decision (EWS)• Assist in assessment of the Council decision• Structured internet monitoring• Further develop links with forensic/toxicology• Trend-spotting- develop integrated approach for
monitoring emerging trends• Initial implementation of monitoring of misuse of
medicinal products• Multidisciplinary project on monitoring illicit drugs
in waste water
10
Improving Europe’s capacity to monitor and evaluate policies 2011 WP
New drugs
Policy
Goodpractice
Main outputs
• Review and develop framework for drug policy analysis
• Study on drug policy advocacy groups• Contribute to the evaluation of the EU
strategy and action plan• And provide appropriate support to the
commission in this area• Model the impact on unemployment on
drug issues
11
Expend BPP and promote cooperation with scientific community 2011 WP
New drugs
Policy
Goodpractice
Main outputs
• Support EU project on standard and guidelines for interventions harm reduction and social rehabilitation
• Expend and continue promoting best practice in Europe
• Promote and facilitate EU research on drug issues
• Net work with scientific community and relevant organisations
12
• Annual report package
• EU drug strategy• Scientific Monograph• Insights• Manuals• Drug policy profiles• Drugs in Focus• Thematic papers• Joint publications• Online tools• Articles
• Annual report• Statistical bulletin• Selected issues (treatment
guidelines, cost of treatment, mortality)
2011 WP
New drugs
Policy
Goodpractice
Main outputs
13
• Annual report package
• EU drug strategy• Scientific Monograph• Insights• Manuals• Drug policy profiles• Drugs in Focus• Thematic papers• Joint publications• Online tools• Articles
• Situation and responses review since 2005
2011 WP
New drugs
Policy
Goodpractice
Main outputs • EMCDDA public website• Best practice portal• ELDD• Country intervention
profiles
14
• Annual report package
• EU drug strategy• Scientific Monograph• Insights• Manuals• Drug policy profiles• Drugs in Focus• Thematic papers• Joint publications• Online tools• Articles
• New groups of psychoactive substances
2011 WP
New drugs
Policy
Goodpractice
Main outputs• European ecstasy market
(Europol)• Guidance on prevention of
infections among IDus (ECDC
15
• Annual report package
• EU drug strategy• Scientific Monograph• Insights• Manuals• Drug policy profiles• Drugs in Focus• Thematic papers• Joint publications• Online tools• Articles
2011 WP
New drugs
Policy
Goodpractice
Main outputs• Emerging drug trends case
study• Drug couriers• New methods for cross
analysis of prevention trials• Drug user perspective in
quitting drug use, etc….
• Cannabis market and production
• Heroin-assisted treatment• Models of dependency and
compulsive behaviour
16
• Annual report package
• EU drug strategy• Scientific Monograph• Insights• Manuals• Drug policy profiles• Drugs in Focus• Thematic papers• Joint publications• Online tools• Articles
2011 WP
New drugs
Policy
Goodpractice
Main outputs
• DRID protocol• Mortality cohort protocol• Guidelines for evaluation
of national drug strategies
• Responding to psychoactive substances
• Minimum quality standard of interventions
• Drug-related research• Khat
17
• Annual report package
• EU drug strategy• Scientific Monograph• Insights• Manuals• Drug policy profiles• Drugs in Focus• Thematic papers• Joint publications• Online tools• Articles
2011 WP
New drugs
Policy
Goodpractice
Main outputs
• New series of national drug policy profiles
Questions and discussion